Veeva Systems Inc.
VEEV
Positions held
Your positionsVEEV isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Veeva Systems operates in a growing healthcare information services industry, benefiting from increasing demand for cloud-based solutions in life sciences.
- In Q3 2026, Veeva reported a revenue of $928 million, a 5% increase from the previous quarter.
- The company's gross margin remained stable at 75% compared to the prior quarter.
- Veeva's high trailing P/E ratio of 46.48 may indicate overvaluation compared to industry peers, which could deter value-focused investors.
- The company's debt-to-equity ratio stands at 2.041, suggesting a higher reliance on debt financing.
- Despite revenue growth, the operating margin has slightly decreased to 29.64% in Q3 2026 from 30.93% in Q2 2026.
Fundamentals
| Market cap | $46.12B | Enterprise value | $39.03B | Trailing P/E | 46.70 | Forward P/E | 27.79 |
| PEG | 1.09 | Price / book | 6.35 | Beta | 0.93 | Dividend yield | 0.00% |
| Revenue growth | 17.6% | Earnings growth | 39.5% | Gross margin | 75.0% | Operating margin | 29.6% |
| Profit margin | 29.3% | ROE | 14.4% | ROA | 7.6% | Debt / equity | 0.02 |
| Current ratio | 5.46 | Free cash flow | $1.26B | Analyst recommendation | buy | Mean target | $295.27 |
| 52w high | $302.17 | 52w low | $148.05 |
Quarterly
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | |
|---|---|---|---|---|---|
| Revenue | $928M | $883M | $836M | $811M | $789M |
| Op margin | 29.6% | 30.9% | 29.4% | 29.7% | 24.8% |
| Net income | $273M | $261M | $244M | $236M | $200M |
| Gross margin | 75.0% | 75.0% | 74.5% | 75.4% | 75.3% |
| Gross profit | $696M | $662M | $622M | $612M | $594M |
| Operating income | $275M | $273M | $246M | $241M | $196M |
- Revenue +5% vs prior quarter ($928M vs $883M).
- Gross margin 75% (was 75% prior quarter).
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $3.2B | $2.7B | $2.4B | $2.2B | — |
| Op margin | 28.7% | 25.2% | 18.2% | 21.3% | — |
| Net income | $909M | $714M | $526M | $488M | — |
| Gross margin | 75.5% | 74.5% | 71.3% | 71.7% | — |
| Gross profit | $2.4B | $2.0B | $1.7B | $1.5B | — |
| Operating income | $916M | $691M | $429M | $459M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
2026-10-09 · Veeva (VEEV) Stock May Be 11% Below Fair Value After Biotech Adoption News
2026-10-08 · 2 Growth Stocks to Buy in October
2026-10-08 · Veeva Systems (VEEV) On Broad Basics Adoption And The Case For An Undervalued Stock
2026-10-08 · Software Leader Veeva Systems Positioned To Hit Buy Points After Nearly Doubling
2026-10-08 · Evercore ISI Adjusts Veeva Systems Price Target to $250 From $185
2026-10-08 · Veeva Summit to Showcase AI Innovations and the Leaders Transforming R&D and Quality
2026-10-08 · Why Is Veeva Systems (VEEV) Drawing Attention After Reaching 175 Biotechs?
2026-10-08 · Jim Cramer Has Reservations About One of These Software Comebacks
2026-10-07 · Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies
2026-10-07 · Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development
2026-10-06 · Sector Update: Healthcare Stocks Rise Premarket Tuesday
Price (daily)
Full chart · RSI · MACD · patterns